Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 6/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325329 | 0.89 | RPS6KB1 (0.43) | LCKCSNK1DRPS6KB1GSK3AGSK3B | |
| SCHEMBL1325671 | 0.88 | GRIN2B (0.39) | LCKGRIN2BSCN9APTGS2 | |
| SCHEMBL18817207 | 0.88 | LCK (0.44) | LCKNR4A2KDM4EALDH1A1HPGD | |
| SCHEMBL1325539 | 0.88 | DCLRE1B (0.40) | LCKCSNK1DGSK3AGSK3BDYRK1A | |
| SCHEMBL1324749 | 0.85 | TRPM8 (0.44) | LCKCSNK1DRPS6KB1GSK3AGSK3B | |
| SCHEMBL1324770 | 0.85 | TRPM8 (0.40) | LCKCSNK1DGRIN2BSCN9APTGS2 | |
| SCHEMBL18816981 | 0.84 | NR4A2 (0.51) | LCKNR4A2KDM4EALDH1A1HPGD | |
| SCHEMBL1324537 | 0.80 | MAPK14 (0.41) | CSNK1DRPS6KB1GSK3AGSK3BDYRK1A | |
| SCHEMBL18816898 | 0.80 | CSNK1D (0.39) | CSNK1DRPS6KB1GSK3AGSK3BDYRK1A | |
| SCHEMBL1325638 | 0.78 | MAPK14 (0.39) | CSNK1DRPS6KB1GSK3AGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193721-B2 | Fused derivatives as PI3Kδ inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193721-B2 | Fused derivatives as PI3Kδ inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193721-B2 | Fused derivatives as PI3Kδ inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2558463-A1 | FUSED DERIVATIVES AS I3 INHIBITORS | Incyte Corporation (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20110281884-A1 | FUSED DERIVATIVES AS PI3KDELTA INHIBITORS | INCYTE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| US-20110281884-A1 | FUSED DERIVATIVES AS PI3KDELTA INHIBITORS | INCYTE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| WO-2011130342-A1 | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS | INCYTE CORPORATION (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130342-A1 | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS | INCYTE CORPORATION (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281884-A1 | FUSED DERIVATIVES AS PI3KDELTA INHIBITORS | PIK3CD, PIK3CA, PIK3CB | LCK 215/4885CSNK1D 685/4885RPS6KB1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.